Alx Oncology Holdings (ALXO) Times Interest Earned (2019 - 2026)
Alx Oncology Holdings (ALXO) posted Times Interest Earned of -$4.94 for Q1 2026, up 91.77% sequentially from -$60.11 in Q4 2025, and up 93.69% YoY from -$2.55 in Q1 2025.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) Times Interest Earned (2019 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Times Interest Earned for 8 years, with the latest figure at -$4.94 in Q1 2026.
- Quarterly Times Interest Earned rose 93.69% year-over-year to -$4.94 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23.77 (up 70.06% YoY) and the FY2025 annual result came in at -$0.69, up 96.59% from the prior year.
- Times Interest Earned grew to -$4.94 in Q1 2026 per ALXO's latest filing, from -$60.11 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$4.94 in Q1 2026 and troughed at -$18340.5 in Q3 2022.
- A 5-year average of -$2144.3 and a median of -$83.21 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2023: Times Interest Earned sank 96919.77% in 2022, then jumped 99.41% in 2023.
- Over 5 years, Times Interest Earned stood at -$139.48 in 2022, then surged by 45.69% to -$75.75 in 2023, then grew by 7.94% to -$69.73 in 2024, then grew by 13.8% to -$60.11 in 2025, then soared by 91.77% to -$4.94 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$4.94, -$60.11, and -$55.23 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -21.24 |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 1.42 |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -0.08 |
| 10 | Alx Oncology Holdings | 273.99 Mn | 273.99 Mn | - | -63.27 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -63.27 |
| Mar 31, 2026 | -57.30 |
| Dec 31, 2025 | -60.11 |
| Sep 30, 2025 | -55.23 |
| Jun 30, 2025 | -65.80 |
| Mar 31, 2025 | -78.37 |
| Dec 31, 2024 | -71.69 |
| Sep 30, 2024 | -73.02 |
| Jun 30, 2024 | -96.79 |
| Mar 31, 2024 | -88.44 |
| Dec 31, 2023 | -115.72 |
| Sep 30, 2023 | -136.25 |
| Jun 30, 2023 | -98.86 |
| Mar 31, 2023 | -83.21 |
| Dec 31, 2022 | -139.48 |
| Sep 30, 2022 | -18,340.50 |
| Jun 30, 2022 | -16,894.50 |
| Mar 31, 2022 | -8,249.00 |
| Dec 31, 2020 | 3,565.00 |
| Sep 30, 2020 | -88.37 |